ProShare Advisors
RNAC icon

ProShare Advisors’s Cartesian Therapeutics RNAC Stock Holding History

ProShare Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-683
Closed -$13.3K – 1974
2024
Q1 		$13.3K Buy
683
+35
+5% +$742 ﹤0.01% 1988
2023
Q4 		$13.4K Sell
648
-189
-23% -$5.64K ﹤0.01% 1939
2023
Q3 		$26.6K Buy
837
+3
+0.4% +$100 ﹤0.01% 1767
2023
Q2 		$28K Buy
834
+480
+136% +$17.2K ﹤0.01% 1819
2023
Q1 		$14.7K Sell
354
-68
-16% -$3.2K ﹤0.01% 1748
2022
Q4 		$14.3K Sell
422
-6
-1% -$255 ﹤0.01% 1819
2022
Q3 		$21K Buy
428
+34
+9% +$1.87K ﹤0.01% 1713
2022
Q2 		$15K Sell
394
-584
-60% -$17.3K ﹤0.01% 1780
2022
Q1 		$36K Sell
978
-240
-20% -$15K ﹤0.01% 2139
2021
Q4 		$119K Buy
1,218
+11
+0.9% +$1.18K ﹤0.01% 2167
2021
Q3 		$151K Sell
1,207
-243
-17% -$29.3K ﹤0.01% 1847
2021
Q2 		$182K Buy
1,450
+348
+32% +$41.4K ﹤0.01% 2168
2021
Q1 		$150K Buy
1,102
+45
+4% +$5.59K ﹤0.01% 2105
2020
Q4 		$96K Buy
+1,057
New +$91.7K ﹤0.01% 1995

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

ProShare Advisors's RNAC Position: Q2 2024 in Review

ProShare Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 683 shares — an estimated $13.3K sold.

ProShare Advisors first reported a position in RNAC in Q4 2020 and held it in 14 quarters. The position peaked at $182K in Q2 2021. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • ProShare Advisors reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ProShare Advisors sold 683 Cartesian Therapeutics shares in Q2 2024, an estimated $13.3K.
  • ProShare Advisors first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 14 quarters.
  • ProShare Advisors's Cartesian Therapeutics position peaked at $182K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on ProShare Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.